These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 27836402)

  • 41. Lead optimization of 4,4-biaryl piperidine amides as γ-secretase inhibitors.
    Close J; Heidebrecht R; Hendrix J; Li C; Munoz B; Surdi L; Kattar S; Tempest P; Moses P; Geng X; Hughes B; Smotrov N; Moxham C; Chapnick J; Kariv I; Nikov G; Burke JE; Deshmukh S; Jeliazkova-Mecheva V; Leach JK; Diaz D; Xu L; Yang Z; Kwei G; Moy L; Shah S; Tanga F; Kenefic C; Savage D; Shearman M; Ball RG; McNevin MJ; Markarewicz A; Miller T
    Bioorg Med Chem Lett; 2012 May; 22(9):3203-7. PubMed ID: 22483609
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Design, synthesis, and structure-activity relationship studies of N-arylsulfonyl morpholines as γ-secretase inhibitors.
    Li H; Xu R; Cole D; Clader JW; Greenlee WJ; Nomeir AA; Song L; Zhang L
    Bioorg Med Chem Lett; 2010 Nov; 20(22):6606-9. PubMed ID: 20933414
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficient inhibition of the Alzheimer's disease beta-secretase by membrane targeting.
    Rajendran L; Schneider A; Schlechtingen G; Weidlich S; Ries J; Braxmeier T; Schwille P; Schulz JB; Schroeder C; Simons M; Jennings G; Knölker HJ; Simons K
    Science; 2008 Apr; 320(5875):520-3. PubMed ID: 18436784
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tricyclic sulfones as orally active gamma-secretase inhibitors: synthesis and structure-activity relationship studies.
    Sasikumar TK; Qiang L; Burnett DA; Cole D; Xu R; Li H; Greenlee WJ; Clader J; Zhang L; Hyde L
    Bioorg Med Chem Lett; 2010 Jun; 20(12):3632-5. PubMed ID: 20493690
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The structure and function of Alzheimer's gamma secretase enzyme complex.
    Krishnaswamy S; Verdile G; Groth D; Kanyenda L; Martins RN
    Crit Rev Clin Lab Sci; 2009; 46(5-6):282-301. PubMed ID: 19958215
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Discovery of a Novel, Potent Spirocyclic Series of γ-Secretase Inhibitors.
    Zhao Z; Pissarnitski DA; Josien HB; Wu WL; Xu R; Li H; Clader JW; Burnett DA; Terracina G; Hyde L; Lee J; Song L; Zhang L; Parker EM
    J Med Chem; 2015 Nov; 58(22):8806-17. PubMed ID: 26496070
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Potency prediction of β-secretase (BACE-1) inhibitors using density functional methods.
    Roos K; Viklund J; Meuller J; Kaspersson K; Svensson M
    J Chem Inf Model; 2014 Mar; 54(3):818-25. PubMed ID: 24456077
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Amino-caprolactam γ-secretase inhibitors showing potential for the treatment of Alzheimer's disease.
    Neitzel ML; Aubele DL; Marugg JL; Jagodzinski JJ; Konradi AW; Pleiss MA; Szoke B; Zmolek W; Goldbach E; Quinn KP; Sauer JM; Brigham EF; Wallace W; Bova MP; Hemphill S; Basi G
    Bioorg Med Chem Lett; 2011 Jun; 21(12):3715-20. PubMed ID: 21571529
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Gamma-secretase inhibitors in Alzheimer's disease therapy].
    Katarína S; Jan K; Kamil K; Kamil M
    Ceska Slov Farm; 2012 Jun; 61(3):93-100. PubMed ID: 22913824
    [TBL] [Abstract][Full Text] [Related]  

  • 50. (S)-N-(5-Chlorothiophene-2-sulfonyl)-beta,beta-diethylalaninol a Notch-1-sparing gamma-secretase inhibitor.
    Cole DC; Stock JR; Kreft AF; Antane M; Aschmies SH; Atchison KP; Casebier DS; Comery TA; Diamantidis G; Ellingboe JW; Harrison BL; Hu Y; Jin M; Kubrak DM; Lu P; Mann CW; Martone RL; Moore WJ; Oganesian A; Riddell DR; Sonnenberg-Reines J; Sun SC; Wagner E; Wang Z; Woller KR; Xu Z; Zhou H; Jacobsen JS
    Bioorg Med Chem Lett; 2009 Feb; 19(3):926-9. PubMed ID: 19097890
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo.
    Hussain I; Hawkins J; Harrison D; Hille C; Wayne G; Cutler L; Buck T; Walter D; Demont E; Howes C; Naylor A; Jeffrey P; Gonzalez MI; Dingwall C; Michel A; Redshaw S; Davis JB
    J Neurochem; 2007 Feb; 100(3):802-9. PubMed ID: 17156133
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Beta-secretase inhibitors in phase I and phase II clinical trials for Alzheimer's disease.
    Moussa CE
    Expert Opin Investig Drugs; 2017 Oct; 26(10):1131-1136. PubMed ID: 28817311
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Gamma-secretase: a complex target for Alzheimer's disease.
    Lundkvist J; Näslund J
    Curr Opin Pharmacol; 2007 Feb; 7(1):112-8. PubMed ID: 17169612
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Diamide amino-imidazoles: a novel series of γ-secretase inhibitors for the treatment of Alzheimer's disease.
    Brodney MA; Auperin DD; Becker SL; Bronk BS; Brown TM; Coffman KJ; Finley JE; Hicks CD; Karmilowicz MJ; Lanz TA; Liston D; Liu X; Martin BA; Nelson RB; Nolan CE; Oborski CE; Parker CP; Richter KE; Pozdnyakov N; Sahagan BG; Schachter JB; Sokolowski SA; Tate B; Van Deusen JW; Wood DE; Wood KM
    Bioorg Med Chem Lett; 2011 May; 21(9):2631-6. PubMed ID: 21269825
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Continuing strategies for inhibiting Alzheimer's gamma-secretase.
    Wolfe MS; Esler WP; Das C
    J Mol Neurosci; 2002; 19(1-2):83-7. PubMed ID: 12212799
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1.
    Li YM; Xu M; Lai MT; Huang Q; Castro JL; DiMuzio-Mower J; Harrison T; Lellis C; Nadin A; Neduvelil JG; Register RB; Sardana MK; Shearman MS; Smith AL; Shi XP; Yin KC; Shafer JA; Gardell SJ
    Nature; 2000 Jun; 405(6787):689-94. PubMed ID: 10864326
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Design, synthesis and biological evaluation of novel dual inhibitors of acetylcholinesterase and beta-secretase.
    Zhu Y; Xiao K; Ma L; Xiong B; Fu Y; Yu H; Wang W; Wang X; Hu D; Peng H; Li J; Gong Q; Chai Q; Tang X; Zhang H; Li J; Shen J
    Bioorg Med Chem; 2009 Feb; 17(4):1600-13. PubMed ID: 19162488
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The discovery of fused oxadiazepines as gamma secretase modulators for treatment of Alzheimer's disease.
    Li H; Qin J; Dhondi P; Zhou W; Vicarel M; Bara T; Cole D; Josien H; Pissarnitski D; Zhu Z; Palani A; Aslanian R; Clader J; Czarniecki M; Greenlee W; Cohen-Williams M; Hyde L; Song L; Zhang L; Chu I; Huang X
    Bioorg Med Chem Lett; 2013 Jan; 23(2):466-71. PubMed ID: 23253441
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Membrane anchored and lipid raft targeted β-secretase inhibitors for Alzheimer's disease therapy.
    Ben Halima S; Rajendran L
    J Alzheimers Dis; 2011; 24 Suppl 2():143-52. PubMed ID: 21460437
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Acylguanidine inhibitors of beta-secretase: optimization of the pyrrole ring substituents extending into the S1' substrate binding pocket.
    Jennings LD; Cole DC; Stock JR; Sukhdeo MN; Ellingboe JW; Cowling R; Jin G; Manas ES; Fan KY; Malamas MS; Harrison BL; Jacobsen S; Chopra R; Lohse PA; Moore WJ; O'Donnell MM; Hu Y; Robichaud AJ; Turner MJ; Wagner E; Bard J
    Bioorg Med Chem Lett; 2008 Jan; 18(2):767-71. PubMed ID: 18068983
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.